Ernst is a business-orientated scientist with broad scientific training in oncology, infectious diseases and chemistry and a strong interest in valorization of science. Ernst holds a PhD in molecular cancer genetics from the Netherlands Cancer Institute (NKI-AvL) after which he continued his career as business developer at TNO, where he gained experience in marketing, business consultancy, international business development and venturing. As associate at Aglaia he is responsible for analysis of investment proposals as well as scouting of new investment opportunities.
InteRNA Demonstrates Preclinical Proof-of-Concept for Lead microRNA Candidate INT-1B3 in a Range of Cancer Models at 2018 AACR Annual Meeting
MIMETAS Secures 20 Million Dollar Series B Financing